Tigecycline Formulation Stabilization Against Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tigecycline, an antibiotic effective against drug-resistant bacteria, degrades rapidly due to oxidative and epimerization processes, limiting its stability in solution and lyophilized forms, necessitating immediate use and costly low-oxygen, low-temperature processing, which restricts flexibility in administration.
Innovation Solution
Formulating tigecycline with a suitable carbohydrate and acid or buffer at an acidic pH to stabilize against oxidative degradation and epimerization, allowing for longer storage and administration times without requiring low-temperature or low-oxygen conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tigecycline is prepared as a lyophilized powder under low-oxygen and low-temperature conditions, then oxidative degradation is minimized, but processing costs increase due to special equipment and handling requirements
Solution Approach 1:
An inert atmosphere (nitrogen or carbon dioxide) is introduced as an intermediary between tigecycline and oxygen during lyophilization and storage. This mediator prevents direct contact between oxygen and tigecycline, eliminating oxidative degradation without requiring expensive low-temperature processing or special equipment beyond standard lyophilization capabilities.
Solution Approach 2:
The patent applies inert atmosphere technology by conducting lyophilization and storage under nitrogen or carbon dioxide environments. This creates an oxygen-excluded environment that prevents oxidative degradation of tigecycline, resolving the contradiction between stability and manufacturing cost by using a chemically inert medium rather than expensive thermal control measures.
2Reliability
If tigecycline is reconstituted and diluted immediately prior to use, then oxidative degradation is minimized, but administrative flexibility is reduced due to tight time constraints
Solution Approach 1:
The reconstituted and diluted tigecycline solutions are stored in inert atmosphere containers (nitrogen or carbon dioxide environments) that prevent oxygen contact. This allows the solutions to be prepared in advance and stored for extended periods without degradation, giving hospital staff flexibility to prepare doses ahead of time without strict immediate-use constraints.
Solution Approach 2:
The patent enables preliminary preparation of tigecycline solutions by allowing reconstitution and dilution to be performed in advance under inert atmosphere conditions. The solutions can be prepared hours or days before administration, eliminating the need for immediate use and providing administrative flexibility while maintaining stability through the inert environment.
3Ease of operation
If tigecycline is stored in solution form, then ease of administration is improved, but stability is reduced due to rapid degradation via oxidation
Solution Approach 1:
Tigecycline solutions are stored in containers filled with inert atmosphere (nitrogen or carbon dioxide) that exclude oxygen. This allows the drug to be in convenient solution form for easy administration while simultaneously preventing oxidative degradation, resolving the contradiction between ease of administration and stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation significantly enhances the stability of tigecycline in both solid and solution states, extending reconstitution and admixture times, providing greater flexibility in hospital settings and reducing production costs.
Implementation Method 1
tigecycline degrades in solution principally via oxidation
Implementation Method 2
stable against both oxidative degradation and epimerization
Implementation Method 3
lyophilizing (freeze-drying) the solution to dryness to form solid cakes
Data Source
AI summary
The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.